About Sequenta
Sequenta is a company based in San Francisco (United States) founded in 2008 by Malek Faham and Thomas Willis was acquired by Adaptive Biotechnologies in January 2015.. Sequenta has raised $43.46 million across 5 funding rounds from investors including Adaptive Biotechnologies, Celgene and Foresite Capital. Sequenta offers products and services including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics. Sequenta operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter San Francisco, United States
- Founders Malek Faham, Thomas Willis
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sequenta Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$43.46 M (USD)
in 5 rounds
-
Latest Funding Round
-
Investors
Adaptive Biotechnologies
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Adaptive Biotechnologies
(Jan 07, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sequenta
Sequenta offers a comprehensive portfolio of products and services, including clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
NGS-based test for assessing minimal residual disease in trials
Platform for immune receptor data analysis in drug development
Tools for T-cell receptor-based antibody therapies
Funding Insights of Sequenta
Sequenta has successfully raised a total of $43.46M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
-
First Round
First Round
(15 Jul 2009)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2014 | Amount | Series D - Sequenta | Valuation |
investors |
|
| Jul, 2013 | Amount | Series C - Sequenta | Valuation |
investors |
|
| Feb, 2012 | Amount | Series B - Sequenta | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sequenta
Sequenta has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Adaptive Biotechnologies, Celgene and Foresite Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sequenta
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Sequenta
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sequenta Comparisons
Competitors of Sequenta
Sequenta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Sequenta
When was Sequenta founded?
Sequenta was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Sequenta located?
Sequenta is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Sequenta a funded company?
Sequenta is a funded company, having raised a total of $43.46M across 5 funding rounds to date. The company's 1st funding round was a Series B of $8.46M, raised on Jul 15, 2009.
What does Sequenta do?
Sequenta was founded in 2008 in San Francisco, United States, within the biotechnology sector. Immuno-sequencing technologies are researched and developed for applications in diagnosing and treating cancer, autoimmune disorders, and infectious diseases. A primary diagnostic test was produced to assess minimal residual disease in hematological cancers. Operations centered on these tools until acquisition by Adaptive Biotechnologies in January 2015 for an undisclosed sum.
Who are the top competitors of Sequenta?
Sequenta's top competitors include Guardant Health, Foundation Medicine and Forty Seven.
What products or services does Sequenta offer?
Sequenta offers clonoSEQ, Adaptive Immunosequencing, and TCR Therapeutics.
Who are Sequenta's investors?
Sequenta has 5 investors. Key investors include Adaptive Biotechnologies, Celgene, Foresite Capital, Mohr Davidow Ventures, and Index Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.